Sentinel Diagnostics announces the launch of the new quantitative serological kits COVID-19

Sentinel Diagnostics announces the launch of the new quantitative serological kits COVID-19

As Sentinal Diagnostics, we are committed to support healthcare professionals to fight COVID-19 pandemic, thus we have developed two new kits to detect the total antibodies (IgA, IgG and IgM) against Spike and Nucleocapside proteins of SARS-CoV-2.

COVID-19 Anti-S1 Total Ab and COVID-19 Anti-NC Total Ab assays are In Vitro Diagnostic tests, for quantitative and qualitative analysis with immunoturbimetric method, designed to process hundreds of results in 1 hour and thousands in a single day when used on our Sentinel SENTIFIT®270 Analyzer or other automated analytical platforms. The first kit detects the total antibodies against the Spike RBD S1 protein, while the second detects the antibodies against Nucleocapsid (NC) protein.

The combined use of Sentinel COVID-19 Anti-S1 Total Ab and COVID-19 Anti-NC Total Ab would help distinguish vaccinated individuals from naturally infected ones as well as they can be used to ascertain the spread of infection in communities.

The tests can be performed together on the same serum sample on our SentiFIT® 270. SentiFIT® 270  is a benchtop automatic analyzer able to process up to 270 samples/hours allowing complete sample tracking and delivering the first results in 10 minutes.

More info are available on the Covid-19 webpage: https://www.sentineldiagnostics.com/covid-19 Abs

If you have any questions, please contact our customer service (please, fill in the form) or contact our commercial department at marketing@sentinel.it.